Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Sep;26(9):2061-8.
doi: 10.1038/leu.2012.115. Epub 2012 Apr 27.

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

R M Stone  1 , T Fischer, R Paquette, G Schiller, C A Schiffer, G Ehninger, J Cortes, H M Kantarjian, D J DeAngelo, A Huntsman-Labed, C Dutreix, A del Corral, F Giles
Affiliations
Clinical Trial

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

R M Stone et al. Leukemia. 2012 Sep.

Abstract

This phase 1b trial investigated several doses and schedules of midostaurin in combination with daunorubicin and cytarabine induction and high-dose cytarabine post-remission therapy in newly diagnosed patients with acute myeloid leukemia (AML). The discontinuation rate on the 50-mg twice-daily dose schedule was lower than 100 mg twice daily, and no grade 3/4 nausea or vomiting was seen. The complete remission rate for the midostaurin 50-mg twice-daily dose schedule was 80% (FMS-like tyrosine kinase 3 receptor (FLT3)-wild-type: 20 of 27 (74%), FLT3-mutant: 12 of 13 (92%)). Overall survival (OS) probabilities of patients with FLT3-mutant AML at 1 and 2 years (0.85 and 0.62, respectively) were similar to the FLT3-wild-type population (0.78 and 0.52, respectively). Midostaurin in combination with standard chemotherapy demonstrated high complete response and OS rates in newly diagnosed younger adults with AML, and was generally well tolerated at 50 mg twice daily for 14 days. A phase III prospective trial is ongoing (CALGB 10603, NCT00651261).

PubMed Disclaimer

Conflict of interest statement

Authors’ Disclosures of Potential Conflicts of Interest

Employment or Leadership Position: Alice Huntsman-Labed, Novartis Pharma AG (C); Catherine Dutreix, Novartis Pharma AG (C); Adam del Corral, Novartis Pharmaceuticals Corporation (C) Consultant or Advisory Role: Richard M. Stone, Genzyme (C), Celgene (C), Ariad (C); Ronald Paquette, Novartis (C); Gary Schiller, Genzme (C); Charles A. Schiffer, Pfizer (C), Micromet (C), Celgene (C), Ambit (C), Ariad (C); Jorge Cortes, Novartis (C), Ariad (C), Ambit (U); Hagop M. Kantarjian, Novartis (C); Daniel J. DeAngelo, Novartis (C); Francis Giles, Novartis (C) Stock Ownership: Gerhard Ehninger, Novartis; Alice Huntsman-Labed, Novartis Honoraria: Thomas Fischer, Novartis; Ronald Paquette, Novartis; Gerhard Ehninger, Novartis Expert Testimony: None Other Remuneration:None

Figures

Fig 1
Fig 1
Schema of dose and schedule of midostaurin administration. Daunorubicin and cytarabine induction (3 + 7) and high-dose cytarabine post-remission therapy was administered on a standard schedule. In addition, patients received midostaurin (indicated by black bars) on one of three dose schedules: I. midostaurin 100 mg twice daily (BID) for 21 or 28 days; II. midostaurin 100 mg twice daily for 14 days; or III. midostaurin 50 mg twice daily for 14 days. Within each dose schedule, patients were assigned to receive midostaurin on day 1 (concomitant with chemotherapy, days 1-7; 14-21 in dose schedules II and III) or day 8 (sequential with chemotherapy; days 8-21 in dose schedules II and III). Open boxes represent values from patients on the concomitant arm (day 1-7 and day 15-22 dosing); closed circles represent values from patients on the sequential arm (day 8-22 dosing).
Fig 2
Fig 2
CONSORT flow diagram. Depicts patient numbers for enrollment, intervention allocation, and follow-up. Abbreviations: AE, adverse event; BID, twice daily. a Three patients (n= 2 from the sequential arm; n = 1 from the concomitant arm) discontinued in complete remission before completing consolidation and were considered as completers by investigators. Open boxes represent values from patients on the concomitant arm (day 1-7 and day 15-22 dosing); closed circles represent values from patients on the sequential arm (day 8-22 dosing).
Fig 3
Fig 3
a. Overall survival probability in patients with FLT3–wild-type and FLT3-mutant AML treated on dose schedule III. Overall survival was assessed without censoring for alternative therapies such as stem cell transplant. b. Disease-free survival probability in patients with FLT3–wild-type and FLT3-mutant AML treated on dose schedule III. Open boxes represent values from patients on the concomitant arm (day 1-7 and day 15-22 dosing); closed circles represent values from patients on the sequential arm (day 8-22 dosing).
Fig 4
Fig 4
a. Median trough concentration-time profile of midostaurin during the first cycle of induction therapy (midostaurin 50-mg twice-daily cohort). b. Median trough concentration-time profile of CGP62221 during the first cycle of induction therapy (midostaurin 50-mg twice-daily cohort). c. Median trough concentration-time profile of CGP52421 during the first cycle of induction therapy (midostaurin 50-mg twice-daily cohort). Open boxes represent values from patients on the concomitant arm (day 1-7 and day 15-22 dosing); closed circles represent values from patients on the sequential arm (day 8-22 dosing).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326–4335. - PubMed
    1. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61:7233–7239. - PubMed
    1. Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat. 2009;12:81–89. - PMC - PubMed
    1. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59–66. - PubMed
    1. Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1:433–443. - PubMed

Publication types

MeSH terms

Associated data